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Neonatal b cells do not secrete glucose-responsive insulin and
are considered immature. We previously showed the transcrip-
tion factor MAFA is key for the functional maturation of b cells,
but the physiological regulators of this process are unknown.
Here we show that postnatal rat b cells express thyroid hormone
(TH) receptor isoforms and deiodinases in an age-dependent pat-
tern as glucose responsiveness develops. In vivo neonatal triio-
dothyronine supplementation and TH inhibition, respectively,
accelerated and delayed metabolic development. In vitro expo-
sure of immature islets to triiodothyronine enhanced the expres-
sion of Mafa, the secretion of glucose-responsive insulin, and the
proportion of responsive cells, all of which are effects that were
abolished in the presence of dominant-negative Mafa. Using chro-
matin immunoprecipitation and electrophoretic mobility shift as-
say, we show that TH has a direct receptor-ligand interaction
with the Mafa promoter and, using a luciferase reporter, that this
interaction was functional. Thus, TH can be considered a physio-
logical regulator of functional maturation of b cells via its induc-
tion of Mafa. Diabetes 62:1569–1580, 2013
b
-Cell replacement therapy is a major goal of diabetes
research. Insulin-positive cells have been success-
fully derived from stem cells (1–4), but these cells
have not been responsive to glucose in vitro and
must be considered functionally immature. Fetal and
neonatal rodent b cells also lack glucose responsiveness
(5) and therefore provide a good model to study the ac-
quisition of glucose responsiveness and b-cell maturation.
Neonatal b cells are characterized by low expression of
many key genes of the specialized b-cell phenotype (6). We
previously showed that in neonatal islets, Mafa is expressed
at ;10% of the adult level and that its adenoviral-mediated
reconstitution to adult levels in P2 islets induced secretion
of glucose-responsive insulin (7). But what regulates Mafa
in vivo? To identify physiological regulators, we considered
the changes that normally occur in the physiological milieu
during the neonatal period (8). During the second postnatal
week, serum thyroxine (T4) (9) and corticosterone (10)
surge and prolactin levels rise by postnatal day 20 (11).
We hypothesized that thyroid hormone (TH) could
physiologically regulate Mafa, enhancing its expression
and driving the maturation of the insulin secretory re-
sponse to glucose in neonatal b cells. TH serum levels start
increasing in parallel with Mafa expression increases, and
TH is important in the postnatal development of the cen-
tral nervous system and the digestive track (8). Inhibition
of TH synthesis prevents or delays maturation of these
systems, and TH administration results in precocious de-
velopment. Triiodothyronine (T3) has been shown to en-
hance the differentiation of a human pancreatic duct cell
line toward a b-cell phenotype (12). Moreover, thyrotoxi-
cosis leads to hyperinsulinemia with increased hepatic
glucose production and insulin resistance (13); hypothy-
roidism reduces production of hepatic glucose and insulin
resistance (14).
The effects of TH are mediated by TH receptors (THRs),
which are members of the nuclear receptor superfamily.
Three major isoforms—THRA1, THRB1, and THRB2—
exhibit similar ligand-dependent regulation of gene activity,
whereas a fourth isoform, THRA2, lacks the ligand-binding
and transactivation domains (15). Different isoforms have
been identiﬁed in whole pancreas during development (16),
and THRA1 has been identiﬁed in adult islet cells (17);
however, little is known about their expression in b cells
during the postnatal period.
The active TH bound to receptors is 3,5,39-T3,a n d
available T3 is derived from the thyroid gland or from
conversion from thyroxine (T4) by type 1 or type 2 iodo-
thyronine deiodinases (D1 and D2). A third deiodinase,
type 3 (or D3), inactivates T3. D3-null animals, which had
higher levels of TH during development, were glucose in-
tolerant with impaired secretion of glucose-stimulated in-
sulin, suggesting that early exposure to high amounts of T3
might be deleterious to developing b cells (18). However,
the role of TH in b-cell development under physiological
conditions as well as the mechanisms involved are still
unclear.
Herein we show that postnatal rat b cells express THR
isoforms and deiodinases in an age-dependent pattern and
therefore have the ability to respond to the rapidly rising
T4 concentration that peaks at about postnatal day 15. In
vivo neonatal T3 supplementation and TH inhibition, re-
spectively, accelerated and delayed metabolic develop-
ment. In vitro exposure of immature islets to T3 enhanced
Mafa expression and increased glucose responsiveness,
effects that were abolished in the presence of dominant-
negative (DN) Mafa. Using chromatin immunoprecipitation
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ORIGINAL ARTICLE(ChIP) and electrophoretic mobility shift assay (EMSA) we
show that TH has a direct receptor-ligand interaction with
the Mafa promoter; using a luciferase reporter, we then
showed that this interaction is functional. Thus, TH is
a physiological stimulus for the postnatal maturation of
functional b cells.
RESEARCH DESIGN AND METHODS
Animals. Female Sprague-Dawley rats with litters of various ages (P0 is day of
birth) were purchased from Taconic Farms (Germantown, NY) and kept under
conventional conditions with free access to water and food. Animals were
killed under anesthesia at postnatal days 2–28 or as an adult; blood was col-
lected by cardiac puncture, and pancreas was excised for histology or islet
isolation. Islets were isolated (19), cultured overnight in RPMI-1640 medium,
and were handpicked to ensure purity. For each sample from postnatal days 2
or 7, islets from 10 pups were pooled; for samples from postnatal days 9 to 28,
islets from 2 or 3 pups were pooled; and for the adult sample, islets from one
animal were used. Three to six samples per age group were included. For
immunostaining, excised pancreas was either ﬁxed for 2 h in 4% para-
formaldehyde for parafﬁn embedding or embedded in optimal cutting tem-
perature medium (Tissue Tek) and was frozen in chilled isopentane. The
Joslin Institutional Animal Care and Use Committee approved all animal
procedures.
Plasma insulin and T4 levels. Plasma insulin and T4 levels were measured
using enzyme-linked immunoassay (ALPCO, Windham NH) and COAT-
A-COUNT total T4 kit (DPC, Los Angeles, CA), as previously described (20).
Neonatal models of T3 supplementation and inhibition of TH synthesis.
Timed-pregnant Sprague-Dawley rats were randomized into one of three
groups:
1) Control pups received subcutaneous injections of 0.9% NaCl daily for 7
days, starting at postnatal day 1.
2) For inhibition of TH synthesis, rats were given tap water ad libitum with 20
mg methimazole (MMI)/100 mL water (21) from birth to postnatal days 15 or
21, when the pups were killed.
3) For T3 supplementation, pups received subcutaneous injections of T3 (0.05
mg/g body weight) daily for 7 days starting on postnatal day 1 (22).
Body weight and fed glucose levels were measured weekly. For in-
traperitoneal glucose tolerance tests, glucose solution was injected in-
traperitoneally (2 g/kg) after fasting for 4 h, and blood glucose levels were
determined at 0, 30, and 120 min. Islets were isolated from T3-treated and
control rats at postnatal day 7 and reported as in vivo.
The effectiveness of treatments was evaluated by growth parameters, T4
levels, and deiodinase activity when the animal was killed (23) (Table 1).
Hepatic D1 activity was measured in 5- to 20-mg liver homogenate with 10
mmol/L dithiothreitol and 1 mmol/L
125IrT3 for 60 min. Background levels were
determined by the addition of 1 mmol/L propylthiouracil (20).
Islet culture: Hormone treatment and adenoviral infection. At postnatal
day 7 or 9, islets were cultured for 4 days in RPMI-1640 medium (20 mmol/L
glucose and 10% charcoal-stripped [CS] FBS) with T3 (150 pmol/L, equivalent to
7.5 pmol/L free T3 in 10% CS-FBS [24]) for RNA or insulin secretion assays. As
an alternative, islets at postnatal day 9 were cultured for 2 days in RPMI-1640
medium in 10% FBS with dexamethasone (50 pmol/L) for RNA.
To test the speciﬁcity of MAFA as the mechanism of T3 effect, islets at
postnatal day 7 were totally dispersed and cultured in RPMI-1640 medium (20
mmol/L glucose, 10% CS-FBS) with or without T3 (7.5 pmol/L free T3) and with
or without adeno-CMV-DN Mafa-Ires-Gfp (DN-Mafa) (25,26) (MOI 2) or con-
trol adeno-CMV-Ires-Gfp (Ad-Gfp). Reaggregated islets were cultured for
4 days for secretion or RNA.
Insulin secretion in vitro. Insulin secretion was measured by static se-
quential incubation in 2.6 mmol/L and 16.8 mmol/L glucose in Krebs-Ringer
bicarbonate buffer (16 mmol/L HEPES and 0.1% BSA; pH 7.4), as previously
described (27). Supernatants and cells were frozen until assayed. As an al-
ternative, we measured insulin secretion of single b cells using the reverse
hemolytic plaque assay (7,28) in which secreted insulin is revealed by the
presence of hemolytic plaques around secreting cells. The percentage of
insulin-secreting cells forming plaques and the area of the plaques were
measured and multiplied to calculate the secretion index, a measure of the
overall secretory activity of b cells.
Quantitative real-time PCR. Total RNA was isolated with a PicoRNA ex-
traction kit (Arcturus) and reverse transcribed (SuperScript reverse tran-
scriptase, Invitrogen, Grand Island, NY). Real-time quantitative PCR used SYBR
green detection and speciﬁc primers (Supplementary Table 1). Samples were
normalized to a control gene (S25), and the comparative threshold cycle
method used to calculate levels of gene expression.
Immunostaining. Parafﬁn sections were incubated at 4°C overnight with
primary antibodies listed in Supplementary Table 2. Apoptosis was assessed
by TUNEL staining using the In Situ Cell Death Detection Kit, Fluorescein
(Roche, Indianapolis, IN) after retrieval of microwave antigen. DAPI was used
for nuclear staining.
For each antigen, all images were taken with the same settings in confocal
mode using a Zeiss LSM 410 or LSM 710 microscope and were handled similarly
in Adobe Photoshop; at least two animals per age were examined.
Morphometric evaluation. Images covering entire whole pancreatic sections
were collected using the LSM 710 tile-scan system. For MAFA nuclear staining,
insulin-positive cells were scored as high, low, or undetected nuclear MAFA.
Data from four or ﬁve individual animals were averaged; between 36 and 58
islets were sampled for each age. For proliferation and apoptosis, insulin-
positive and Ki-67-positive or TUNEL-positive cells were counted in 160–327
islets and 2,764–6,189 cells per group; data from individual animals (n = 3–5)
were averaged. b-Cell mass was calculated by multiplying the relative area of
b cells by the pancreatic weight (29). The densitometric mean of the intensity
of MAFA staining was calculated using the AxioVision Measure feature and
were considered a reﬂection of protein levels (n = 6–7 animals per group).
Cross-sectional area of the b cell was used as an indicator for cell size and was
determined by dividing the number of nuclei in a given insulin-positive area;
7,000–8,794 nuclei were counted among four animals in each group.
Cell line culture. INS-1 cells maintained in RPMI-1640 medium containing 11
mmol/L glucose + 10% FCS, 10 mmol/L HEPES, 2 mmol/L L-glutamine, penicillin/
streptomycin, 1 mmol/L sodium pyruvate, and 20 mmol/L b-mercaptoethanol
were switched to RPMI-1640 medium containing 1.6 mmol/L glucose + 10%
TABLE 1
Effects of thyroid supplementation or diminished TH synthesis with or without partial replacement on body and pancreatic weight and
an index of thyroid status
Thyroid supplementation (n =9 –32)
Control at P7 Treated with T3 at P7* Control at P11 Treated with T3 at P11†
Body weight (g) 15 6 0.3 17 6 0.4‡ 21 6 0.3 23 6 1§
Pancreas weight (mg) 50 6 10 80 6 2‡ 70 6 4 100 6 7§
D1 liver activity (pmol/min/mg) 21 6 33 6 6 4‡ 41 6 67 3 6 15§
T4 serum levels (mg/dL) 2.0 6 0.4 0.3 6 0.2‡ 2.12 6 0.5 0.2 6 0.09‡
Diminished TH synthesis (n =4 –5)
Control at P15 P15 + MMI Control at P21 P21 + MMI
Body weight (g) 33 6 1.3 27 6 1¶ 46 6 2.5 36 6 3.1§
Pancreas weight (mg) 140 6 2 120 6 5¶ 410 6 2 110 6 3¶
D1 liver activity (pmol/min/mg) 62 6 54 8 6 6 176 6 15 48 6 9¶
T4 serum levels (mg/dL) 6 6 0.3 ND 3.0 6 0.3 0.8 6 0.3¶
Values are presented as means 6 SEM. * Thyroid supplementation model (P1–P7). †Thyroid supplementation model (P1–P11). §P # 0.04 with
respect to age-matched controls. ‡P # 0.004 with respect to age-matched controls. ¶P # 0.00001 with respect to age-matched controls. ND, no
data; P, postnatal day.
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and actinomycin D (5 mg/mL). MIN-6 cells, maintained in high-glucose
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 15% FBS,
were switched to high-glucose DMEM with 15% CS-FBS and T3 (10 nmol/L)
for 24 h; they then were harvested for ChIP or to assess the effect of MMI (1.5
mmol/L, 0.15 mmol/L, and 0.015 mmol/L) on gene transcription.
For the luciferase reporter construct, a 10-Kb Nhe1-Fse1 fragment from the
BAC mouse genomic library clone 128L24 spanning the mouse Mafa promoter
to downstream of the transcription start site was cloned into HindIII-BglII cut
–238 wild-type luciferase plasmid (30). Renilla luciferase in a SacI backbone
was used as a transfection control. For transient transfections, MIN-6 cells
were transfected using lipofectamine and 7 mgo fﬁnal DNA and grown in high-
glucose DMEM with/without 100 nmol/L T3 for 24 h.
ChIP assay. Rabbit anti-THR (TRa/b, Santa Cruz FL-4083) was used with the
Imprint ChIP kit (Sigma Aldrich, St. Louis, MO; CHP1) by following manu-
facturer’s instructions. DNA from 250,000 cells was used for each condition in
four independent experiments. Samples were analyzed by quantitative PCR
using speciﬁc primers for three putative thyroid response elements (TREs; S1,
S2, and S3) (Supplementary Table 1) and were run on gels.
Gel-mobility shift assay (EMSA). Nuclear extracts were obtained from
HEK1 cells transfected with Thrb, or untransfected cells as controls, using the
NucBuster Protein Extraction Kit (Novagen, EMD Biosciences, San Diego,
CA) following the manufacturer’s instructions. Twenty micrograms of nuclear
extract were incubated with 80 pmol/L of double-stranded oligonucleotides,
reproducing the potential TRE S3 in the rat Mafa gene or the reported TRE
of D1 (31) at room temperature for 30 min. The reaction buffer for binding
was 75 mmol/L Tris (pH 7.8), 264 mmol/L potassium chloride, 1.5 mmol/L
EDTA, 30 mmol/L b-mercaptoethanol, 30% glycerol, and 1.2 mg/mL BSA. In
some of the binding assays, anti-THRB antiserum (Afﬁnity Bioreagents,
Golden, CO) or a random antibody were added 1 h before addition of the
DNA probes. After the binding reactions, samples were analyzed by sepa-
ration on 10% polyacrylamide gel in 13 Tris-acetate-EDTA buffer followed
by 40 min of staining with SYBR green EMSA nucleic acid gel stain (Mo-
lecular Probes).
Data analysis. Data are shown as mean 6 SEM. For statistical analysis, un-
paired Student t tests were used to compare two groups, and one-way ANOVA
followed by a Bonferroni post hoc test were used to compare more than two
groups. A P value ,0.05 was considered statistically signiﬁcant.
RESULTS
Postnatal glucose and insulin levels change con-
currently with expression of TH, deiodinases, and
THR. Blood glucose levels at postnatal day 2 were signif-
icantly lower than levels in adults (Fig. 1A), but they in-
creased, peaking at postnatal day 21 at a level 20% higher
than that of adults. Perhaps as a result of rising plasma
glucose levels and as part of the functional maturation
process of b cells, plasma insulin levels peaked at post-
natal day 11, with levels threefold higher than in newborns
or adults (Fig. 1B). During the ﬁrst postnatal month (Fig.
1C), the rate of glucose disposal evaluated by the area
under the curve (AUC) of intraperitoneal glucose toler-
ance test was progressively enhanced; that at postnatal
days 7 and 11 were slower (high AUC values) than at later
ages. Adult values were not yet achieved by postnatal day
21.
For TH to physiologically regulate the functional de-
velopment of b cells, its serum level and the tissue regu-
lation of biologically active T3 must be sufﬁcient and its
receptors must be expressed by b cells. Serum T4, the
principal circulating TH, steadily increased over the ﬁrst 2
weeks, peaking at about twice adult levels at postnatal day
15 before falling to adult levels by postnatal day 21 (Fig.
1D). Because tissue concentrations of T3 are determined
by deiodinases as well as by serum T3, we measured the
islet expression of deiodinases Dio1, Dio2, and Dio3
transcripts during postnatal development (Fig. 1E). Dio1
mRNA in islets increased throughout the postnatal period;
its positive regulation by TH provides an increased para-
crine supply of T3 as the islet develops. In contrast,
expression of both Dio2 and Dio3 fell during the postnatal
period.
D1 and D3 proteins were examined by immunostaining
(Supplementary Fig. 1) in pancreas from animals at post-
natal day 7 and adult animals. The small number of islets
obtained from rats at postnatal day 7 precludes protein
quantiﬁcation using Western blots. However, careful ti-
tration of antibody, parallel staining, and confocal imaging
allowed assessment of protein levels by differences in in-
tensity. Islet D1 protein was much lower at postnatal day 7
than in adults (Supplementary Fig. 1A), although its mRNA
level did not differ. This discrepancy might reﬂect de-
velopmental differences in the synthesis of selenoproteins
that occur downstream of transcription (32). In contrast,
D3 (Supplementary Fig. 1B) had very strong cytoplasmic
localization in islets at postnatal day 7 and became almost
undetectable in adult islets.
As serum T4 increased, islet expression of thyroid
receptors increased at both mRNA and protein levels.
Thra mRNA increased sharply between postnatal days 7
and 9; they were sixfold higher in islets at postnatal day 9
than in adults (Fig. 1F) and decreased to adult levels by
postnatal day 15. By immunostaining (Fig. 2A), nuclear
THRA protein (both the T3-binding THRA1 and the non-T3-
binding THRA2 isoforms are recognized by the antibody)
increased from postnatal day 7 to day 10 but became much
lower by adulthood (Fig. 2C). Similarly, Thrb mRNA in-
creased between postnatal days 7 and 9 and decreased to
adult levels by postnatal day 15 (Fig. 1F). THRB protein
also increased by postnatal day 7 but was mainly cyto-
plasmic; nuclear THRB localization was seen only by
postnatal day 15 and increased in the adult (Fig. 2B and C).
Comparison of mRNA expression of Thra and Thrb in
islets (Supplementary Fig. 2) shows a change in pre-
dominant receptor isoform through development: Thra
predominates at early ages, Thra and Thrb are equal from
postnatal day 9 to 15, after which Thrb becomes the pre-
dominant isoform in islets.
T3 supplementation until postnatal day 7 accelerated
metabolic development. To analyze the direct effects of
TH, newborn rats were injected with T3 from postnatal
days 1 to 7. As expected, this supplementation increased
body and pancreatic weights, reduced T4 levels (because
of suppression of thyrotropin by T3), and increased D1
activity in the liver (Table 1). The pancreas of animals
treated with T3 had greater density of both acinar and islet
cells (Fig. 3A), greater b-cell proliferation (20% vs. 8%
Ki-67
+insulin
+ cells in untreated animals) (Fig. 3B and C),
and no change in the frequency of apoptotic b cells (Fig.
3D). Their b-cell mass was unchanged (Fig. 3E), but their b
cells were smaller (Fig. 3F), with no signiﬁcant change in
the number of cells (Fig. 3G). Fasting glucose levels were
lower (Fig. 3H) and fed plasma insulin levels elevated (Fig.
3I), but their response to intraperitoneal glucose tolerance
tests were not different (data not shown). These results
show that T3 supplementation enhanced the functional
development of b cells.
Inhibition of TH synthesis delayed pancreatic
development. Animals treated with MMI from birth until
postnatal day 15 or 21 were conﬁrmed as having hypo-
thyroidism because of delayed growth with lower body
and pancreatic weights, decreased circulating T4 (due to
inhibition of TH synthesis from the thyroid gland), and
decreased activity of D1 in the liver (Table 1). At postnatal
day 15 there was no change in pancreatic cell density
(Supplementary Fig. 3A), b-cell proliferation (Supplementary
C. AGUAYO-MAZZUCATO AND ASSOCIATES
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animals treated with MMI at postnatal days 15 and 21 had
lower fasting blood glucose levels than their untreated age-
matched controls (Supplementary Figs. 3D and 4A), similar
to that of younger animals (Fig. 1A). Compared with
untreated controls, plasma insulin levels of animals treated
with MMI were lower at postnatal day 15 (Supplementary
Fig. 3E) but were ﬁvefold higher at postnatal day 21 (Sup-
plementary Fig. 4B); values were similar to those at postnatal
day 11, when plasma insulin levels peak (Fig. 1B). The
FIG. 1. Metabolism and thyroid status change over the ﬁrst postnatal month. Values shown as means 6 SEM. A: Fed blood glucose (n =5 –27 animals
per age; *P < 0.0001); B: plasma insulin (n = 4 animals per age; *P < 0.04). AUC for intraperitoneal glucose tolerance test (C) and serum T4 (D)
seen at different ages; n =5 –27 animals per age, *P < 0.0001 with respect to the previous age in C and D. Deiodinase (Dio1, type 1; Dio2, type 2;
Dio3, type 3) (E) and thyroid receptor isoform mRNA (F) over the same time course by quantitative PCR; the same samples are used for both.
Data are expressed as -fold change with respect to adult levels (10 weeks old) using S25 as the internal control gene (n =4 –6 samples per age, each
pooled from 3–10 animals; *P £ 0.0001).
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delayed by inhibiting T4 synthesis (Supplementary Fig. 3G
and Fig. 1C). Animals treated with MMI at postnatal day 21
had glucose clearance similar to untreated animals at post-
natal day 7 (Fig. 1C). Animals treated with MMI at postnatal
day 15 were not as affected, possibly because of shorter
treatment and differences in T3 sensitivity of other glucose-
disposing tissues. Overall, the lack of TH during the postnatal
period delayed the development of efﬁcient glucose disposal.
Local regulation of TH action in postnatal rat islets
by T3 or MMI treatment. Systemic changes in TH status
can be regulated by local changes in T3 concentrations by
deiodinases in target tissues. Changing levels and isoforms
of thyroid receptors also potentially regulate local TH
effects. Islets from animals treated with T3 at postnatal day
7 had increased nuclear THRA (Fig. 4A) and cytoplasmic
THRB protein (Fig. 4C), suggesting more functional
receptors. In animals treated with MMI at postnatal day 21
(Fig. 4B and D), both THRA and THRB had the non-
functional cytoplasmic localization typical of younger
ages. Deiodinase changes also reﬂected the hormonal
status, with increased Dio1 and Dio3 mRNAs in islets after
T3 treatment (Fig. 4E) and reduced Dio1 and Dio3 and
elevated Dio2 mRNA levels (Supplementary Fig. 3F) after
MMI treatment until postnatal day 21. This conﬁrmation
that normal neonatal changes in deiodinases and thyroid
receptors were replicated by external manipulation of TH
status suggests that the endogenous events are causally
related to the TH status.
In vivo T3 modulation affected Mafa gene expression
and its protein nuclear translocation. Islet transcrip-
tional proﬁle changed with in vivo T3 treatment (Fig. 4E
and F): Mafa, Mafb, Pgc1a (peroxisome proliferator–
activated receptor g coactivator-1 a), and Thrb mRNA
increased; Pdx1 and Neurod1 mRNA were unchanged;
and Rest (RE1-silencing transcription factor) mRNA de-
creased. In contrast, Mafa decreased at postnatal day 15
with MMI treatment (Supplementary Fig. 5D and Sup-
plementary Table 3); partial T3 supplementation reversed
this decrease. Mafb, preproinsulin, Ins2, Glp1r,a n dThra
mRNAs increased and Rest mRNA decreased in P15 islets
(Supplementary Table 3). Rest, Thra,a n dThrb mRNAs
FIG. 2. Changing pattern of THR isoform proteins over the neonatal period shown by immunostaining. THRA protein (A, red) and THRB1 protein
(B, red) in insulin-expressing (green) b cells change in intensity and location from postnatal day (P) 2 to adult. C:( top) Nuclear localization of
THRA or THRB (green) in insulin-positive cells (red) shown at a higher magniﬁcation and costained with nuclear stain DAPI (blue); C:( bottom)
red channel deleted for visualization of THR. Representative confocal images taken in parallel at the same settings for each protein so the dif-
ferences in intensity reﬂect the differences in protein. n = at least three animals per group.
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sulin staining was more intense in the T3-treated group and
less intense in MMI-treated animals (Fig. 5A).
T3 supplementation increased MAFA protein both in
nuclear location (Fig. 5A) and amount (Fig. 5B). In pups
treated with T3 at postnatal day 7, 93% of b cells had nu-
clear MAFA compared with only 62% in untreated pups
(Figs. 5A and C); 51% of T3-treated pups had MAFA
high
nuclear staining compared with 10% of untreated animals.
The observed effect of T3 on MAFA translocation could be
an indirect effect mediated by altering the redox state of
the cell (33) through enhancement of mitochondrial func-
tion following increased expression of Pgc1a (Fig. 4C). It
is surprising that even with the increased nuclear expres-
sion of MAFA, glucose-stimulated insulin secretion was
not increased in islets from T3-treated animals (Fig. 5D). In
contrast, hypothyroidism at postnatal day 15 decreased
Mafa mRNA levels (Supplementary Fig. 5D) and protein
(Supplementary Fig. 5A and B) without changes in loca-
tion (Supplementary Fig. 5C). MMI treatment also de-
creased b-cell function as estimated by homeostasis model
assessment-B index (Supplementary Fig. 5E) (18). The
direct effect of MMI on transcription was ruled out be-
cause no signiﬁcant changes were found in the above
genes after culturing MIN-6 cells in the presence of MMI
(Supplementary Fig. 5F).
In vitro T3 speciﬁcally increased Mafa mRNA and
improved glucose-stimulated insulin secretion. Be-
cause the in vivo data may be confounded by the effects
on insulin sensitivity by thyrotoxicosis or hypothyroidism
(14), we developed an in vitro system to directly test
whether increasing Mafa was the mechanism mediating
the T3-maturation effect. DN MAFA lacks an N-terminal
transactivation domain and can form heterodimers with
endogenous MAFA, impairing its ability to activate target
genes (25). In T3-treated Ad-Gfp transduced islets, Mafa
mRNA increased signiﬁcantly (Fig. 6A), conﬁrming the in
vivo T3 results (Fig. 4F); glucokinase mRNA also in-
creased. It is important to note that these increases were
absent in T3-treated islets infected with Ad-DN-Mafa,i n -
dicating a speciﬁcr o l eo fM A F Ai nT 3-mediated effects.
Interestingly, the T3-induced Mafa increase was inhibited
i nt h ep r e s e n c eo fD N - Mafa, suggesting a positive feed-
back mechanism of MAFA upon its own expression.
FIG. 3. In vivo T3 treatment from birth until postnatal day (P) 7 affects pancreatic structure, b-cell dynamics, and glucose homeostasis. Repre-
sentative pictures of acinar cell density (A, hematoxylin stained) and replicating b cells (B, insulin [red] and Ki-67 [green]) in pancreatic sections
from T3-treated and control rats at P7. b-Cell proliferation (Ki-67
+; n = 160–327 islets) (C); apoptosis (TUNEL staining; n = 160–178 islets) (D);
b-cell mass (n =6 –7 animals) (E); mean cross-sectional area (cell size; n = 7,000–8,794 cells per condition) (F); calculated number of b cells per
pancreas (n =3 –4 animals) (G); fasting blood glucose (n =8 –9 animals) (H); and fed plasma insulin (n =2 1 –22 animals; controls: 0.4 6 0.03 vs. T3
treated: 0.5 6 0.04 ng/mL) (I) levels for T3-treated and control animals at P7. Values shown as mean 6 SEM; *P < 0.01 with respect to untreated
animals.
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sulin secretion. In static incubations at postnatal day 7,
islets, whether untreated or Ad-Gfp infected, had little
response to 16.8 mmol/L glucose (Fig. 6B), whereas T3-
treated islets, both uninfected and Ad-Gfp infected, had
insulin secretion increased 5.5-fold (Fig. 6B). This effect
also was abolished in the presence of Ad-DN-Mafa.
Using the reverse hemolytic plaque assay to evaluate
insulin secretion from individual b cells (Fig. 6C), the
effect of T3 on glucose responsiveness was shown to
result from an increased proportion of insulin-secreting
cells (Fig. 6D).
Glucocorticoids inhibit the effects of T3 on glucose-
stimulated insulin secretion. Paradoxically, glucose-
stimulated insulin secretion was not increased in islets
from animals treated with T3 in vivo (Fig. 5D), as was
expected from our in vitro studies (7) and those described
earlier. However, T3 affects the maturation of other tis-
sues, including the adrenal gland (34), so the blunted in
vivo glucose responsiveness may have resulted from in-
creased glucocorticoids. In untreated animals, circulating
corticosterone was quite low after birth and increased only
modestly by postnatal day 15 and then surged to adult
levels (Supplementary Fig. 6A). Glucocorticoid receptor
FIG. 4. T3 treatment results in differential changes of thyroid receptor proteins and islet gene expression. Islets from T3-treated and untreated
animals at postnatal day (P) 7 immunostained for THRA (A) and THRB (C) or from MMI-treated rats at P21 stained for THRA (B) and THRB (D).
Representative confocal images were taken at the same settings for each protein so differences in intensity reﬂect differences in protein. At least
three animals each group. Changes in Dio1, Dio2, and Dio3 (n =3 )( E) and key islet gene (n = 18) (F) mRNA in islets isolated from T3-treated and
untreated control pups by quantitative PCR at P7. Values shown as mean 6 SEM; *P < 0.05 with respect to control animals at P7.
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secretion. A: Representative images from T3-treated and control animals at postnatal day (P) 7 immunostained for insulin (green) and MAFA
(red); bottom panels show only the red channel for MAFA visualization. B: Intensity was quantiﬁed as densitometric mean of MAFA staining from
at least three animals per group. C: Nuclear localization of MAFA in islets of animals treated with T3 increased compared with untreated controls
at P7. Quantiﬁcation of 600–2,200 insulin
+ cells from four or ﬁve animals for each group. D: Glucose-stimulated insulin secretion in static incu-
bations of islets freshly isolated from in vivo T3-treated animals at P7 or control animals (n =5 –6 experiments). Values shown as mean 6 SEM;
*P < 0.02 with respect to controls.
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20.5 to postnatal day 28 (Supplementary Fig. 6B). How-
ever, with T3 supplementation, corticosterone levels at
postnatal day 7 were twice the normal values and were
comparable with those at postnatal day 11 (Supplementary
Fig. 6C). In contrast, after MMI treatment, corticosterone
levels were reduced at postnatal day 21 (Supplementary
Fig. 6D). These data indicate a rapid T3-dependent change
in adrenal function that could affect in vivo islet function
over the neonatal period.
To assess whether increased glucocorticoids explained
the difference in functional maturation of in vitro and in
vivo T3 treatments, islets at postnatal day 9 were cultured
for 48 h with T3, dexamethasone, or both. In islets cultured
with T3 alone, Mafa mRNA was increased signiﬁcantly
(Supplementary Fig. 6E), consistent with islets from ani-
mals treated with T3 at postnatal day 7 (Figs. 4F and 6A).
However, in islets cultured in the presence of dexameth-
asone, with or without T3, Mafa levels remained un-
changed and Pdx1 mRNA was signiﬁcantly suppressed
compared with untreated controls (Supplementary Fig.
6E). Insulin secretion was blunted in similarly cultured
islets at postnatal day 9 (Supplementary Fig. 6F). These
results suggest that islets from animals treated with T3 in
vivo lacked enhanced glucose-stimulated insulin secretion
due to the counter effects of increased glucocorticoids.
T3 directly enhanced Mafa transcription. To analyze
the mechanism by which T3 regulates Mafa expression, we
used b-cell lines (INS-1 and MIN-6), both of which express
THRA and THRB (data not shown). T3 increased Mafa
mRNA transcriptionally rather than by enhancing its sta-
bility, as shown by a 90% inhibition of Mafa mRNA in the
presence of transcription inhibitor actinomycin D (Fig.
7A).
For T3 to have direct effect on Mafa transcription, THR
must bind to TREs. Using AliBaba 2.1 software, we found
potential TRE motifs in the proximal promoter and coding
sequence of mouse Mafa and designed quantitative PCR
primers for them (Supplementary Table 1). In ChIP assay
with MIN-6 cells (Fig. 7B–D), S2 had 2-fold and S3 had 10-
fold enrichment with respect to IgG, indicating both were
TREs. Further evidence of binding of THR to S3 is pro-
vided by EMSA, in which a band observed in the presence
of HEK1 nuclear extract from cells transfected with Thr
expression plasmid was inhibited upon incubation with
antibody against THR (Fig. 7E), suggesting a speciﬁc dis-
ruption of the THR:S3 interaction. In addition, in a lucifer-
ase assay using a reporter construct containing the Mafa
gene 59-promoter region (S3 was not included) (Fig. 7F),
T3 induced a signiﬁcant increase of luciferase activity, in-
dicating S2 is active in the presence of T3 and increases
Mafa transcription. The modest size of the increase in lu-
ciferase activity is primarily the result of the lack of the S3
site in the construct and the high basal Mafa/luciferase
expression in the MIN-6 cells, limiting the impact of T3 on
the transcription of Mafa/luc gene. Overall, these results
indicate that T3 regulates Mafa transcription through di-
rect receptor-ligand interaction.
DISCUSSION
Previously we showed that overexpression of Mafa in
neonatal islets to approximately adult Mafa mRNA levels
induced glucose-responsive insulin secretion and thus the
functional maturation of b cells (7). The data presented
here support TH as a physiological regulator of Mafa
FIG. 6. In vitro T3 selectively increased Mafa mRNA and enhanced
glucose-stimulated insulin secretion. A: Culture for 4 days with T3 (7.5
pmol/L free T3) induced changes in key islet mRNA levels in islets
isolated from animals at postnatal day (P) 7 and infected with either
control Ad-Gfp (black bars) or DN Mafa (white bars) as normalized to
those of Ad-Gfp without T3 treatment. (*P < 0.04 respect to Ad-Gfp;
+P < 0.05 respect to Ad-Gfp+T3; n =4 –7). B: Insulin secretion from
similarly infected and cultured islets at P7 in response to 2.6 mmol/L
glucose (black bars) and 16.8 mmol/L glucose (white bars) in sequential
static incubations (seven experiments for Ad-Gfp +T3 and four for Ad-
Gfp +T3 +DN-Mafa;* P < 0.04 with respect to Ad-Gfp). C:T 3-enhanced
glucose-responsive insulin secretion was conﬁrmed by reverse hemo-
lytic plaque assay for individual cell secretion, showing an increased
percentage of insulin-secreting cells (D) (three experiments; *P £
0.006 with respect to 2.6 mmol/L glucose). Values shown as mean 6
SEM.
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Increased expression of THR and increased serum T4
levels accompanied the increased Mafa mRNA between
postnatal days 7 and 9. Islets treated with T3 in vitro at
postnatal day 7 showed increased glucose responsiveness
with a greater proportion of responsive b cells. Impor-
tantly, expression of DN-MAFA blocked secretion of
glucose-responsive insulin and the increased Mafa mRNA.
These data, along with our previous work (7), indicate that
T3 induction of glucose responsiveness was dependent on
MAFA. Moreover, the thyroid receptor directly interacts
with two putative TREs in the Mafa gene. In vivo manip-
ulation of TH (treatment with T3 or MMI) resulted in the
expected change in Mafa expression, demonstrating the
importance of this mechanism during normal physiological
development.
TH is a known regulator of development in different
tissues, yet its developmental effects on b-cell function
have not been described. Previous studies showed that the
T3-THRA complex enhanced proliferation of RINm5f cells
(35) and that THRA knockout mice had greater whole-
body insulin sensitivity (36). We now show that Mafa is
a direct target of TH in b cells. The physiological impor-
tance of T3 regulation of islet development is underscored
by our in vivo models of T3 modulation.
Although a postnatal switch of thyroid receptor isoforms
has been described in the heart, dorsal root ganglia, and
sciatic nerve with Thra characteristic of immature tissues
and Thrb characteristic of functionally mature tissues
(37,38), such an isoform switch had not been previously
described for b cells. Comparison of the relative mRNA
expression of the isoforms shows that Thra predominates
FIG. 7. T3 directly enhanced Mafa transcription. A: Increase of Mafa mRNA induced in INS-1 cells by T3 was ablated by incubation with actino-
mycin D (ActD). Culture with T3 in 1.6 mmol/L glucose for 6 h (values shown as mean 6 SEM; *P < 0.03; n =3 –6 independent experiments).
B: Schema of the murine Mafa promoter and coding sequence. The top arrow indicates the transcription start site. The black ovals indicate the
experimentally tested TRE sites by ChIP: site 1 (S1), site 2 (S2), and site 3 (S3). The TREs are localized at 22,342/–2,354, 21,927/–1,946 and +647/
+659. The ampliﬁed sequences are shown as is their conservation in other species. S1 is not conserved in humans or rats, whereas S2 is conserved
in rats but not in humans. C: In ChIP studies of MIN-6 cells using an antibody against THR, putative TREs from S2 and S3 showed direct binding of
the THR, but no binding was evident at S1. Gel representative of three or four experiments. D: Quantitative PCR products from ChIP-ampliﬁed
DNA with corresponding IgG, RPII, and input. (values shown as mean 6 SEM; *P < 0.03; n =3 –4 controls). E: Electrophoretic mobility shift assay
showing a band observed in the presence of HEK1 nuclear extract from cells transfected with Thr expression plasmid that was inhibited upon
incubation with antibody against. S3, potential TRE Site 3 in Mafa cds; NE, nontransfected nuclear extract; D1 TRE, known TRE in Dio1 promoter;
IgG, unspeciﬁc antibody; a-THR, antibody against Thr. F: A dual luciferase reporter assay using a ﬁreﬂy luciferase reporter construct with the
59 Mafa promoter region in MIN-6 cells grown in high-glucose DMEM
+/2 100 nmol/L T3 for 24h. Renilla luciferase in a SacI backbone was used as
a transfection control (values shown as mean 6 SEM; *P < 0.01; n = 3). (A high-quality color representation of this ﬁgure is available in the online
issue.)
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postnatal days 9 to 15, and that Thrb becomes the pre-
dominant isoform in adult islets. At the protein level, b
cells expressed both THRA and THRB at postnatal day 7,
but the “immature” isoform THRA had nuclear localization
between postnatal days 7 and 15, whereas the THRB iso-
form was mainly cytoplasmic, suggesting that THRA
mediates TH effects on b cells during the early postnatal
period. THRB showed nuclear translocation only at post-
natal day 15, which was when T3 plasma levels peaked.
Nucleocytoplasmic shuttling of both THRA and THRB
have been described in other cell types (39–41) and can be
mediated by T3 in an energy-dependent process (39); their
nuclear export is considered passive (40), but it is unclear
why there is differential shuttling of the two isoforms.
We also showed that the effects T3 has on other tissues
could inﬂuence the observed phenotype. The surprising
absence of glucose-stimulated insulin secretion in islets
from pups treated with T3 until postnatal day 7 was likely
due to the accelerated maturation of the adrenal gland
induced by T3. At birth the adrenal lacks full function, and
circulating corticosterone increases only gradually after
postnatal day 7 until about postnatal day 15, when a surge
occurs (10). Size of the adrenal gland and circulating
corticosterone levels previously have been directly related
to circulating T3 levels (42). In our studies, corticosterone
levels doubled in animals that received T3 supplementation
and signiﬁcantly decreased in those in which T4 synthesis
was inhibited. Even low concentrations of dexamethasone
decreased Pdx1 mRNA and blocked the stimulatory
effects of T3 on Mafa mRNA and insulin secretion.
In conclusion, we have shown that TH is a physiological
regulator of b-cell maturation, a process mediated through
direct interaction of THR and the Mafa promoter. In vitro,
the active hormone T3 increased glucose-stimulated
insulin secretion and potentially could have a similar
maturation role for in vitro stem cell–derived b cells.
Identiﬁcation of additional physiological regulators that
drive b-cell maturation and glucose responsiveness should
lead to effective strategies for developing fully mature in
vitro–derived b cells for replacement therapy for diabetes.
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